Evidence map›Paper›PMID 37616059›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2023

Amphiphilic Molecules Exhibiting Zwitterionic Excited-State Intramolecular Proton Transfer and Near-Infrared Emission for the Detection of Amyloid β Aggregates in Alzheimer's Disease.

Zhengxin Yu, Yusuff Moshood, Marcin K Wozniak, Shrey Patel, Karna Terpstra, Daniel A Llano, Lawrence W Dobrucki, Liviu M Mirica

Open access · bronzeAbstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Zhengxin YuDepartment of Chemistry, Beckman Institute for Advanced Science and Technology, The Neuroscience Program, Carle Illinois College of Medicine, University of Illinois at Urbana-Champaign, 600 S. Mathews Avenue, Urbana, Illinois, 61801, USA.ORCID https://orcid.org/0000-0002-3592-9704
Yusuff MoshoodDepartment of Chemistry, Beckman Institute for Advanced Science and Technology, The Neuroscience Program, Carle Illinois College of Medicine, University of Illinois at Urbana-Champaign, 600 S. Mathews Avenue, Urbana, Illinois, 61801, USA.
Marcin K WozniakBeckman Institute for Advanced Science and Technology, Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
Shrey PatelDepartment of Chemistry, Beckman Institute for Advanced Science and Technology, The Neuroscience Program, Carle Illinois College of Medicine, University of Illinois at Urbana-Champaign, 600 S. Mathews Avenue, Urbana, Illinois, 61801, USA.
Karna TerpstraDepartment of Chemistry, Beckman Institute for Advanced Science and Technology, The Neuroscience Program, Carle Illinois College of Medicine, University of Illinois at Urbana-Champaign, 600 S. Mathews Avenue, Urbana, Illinois, 61801, USA.
Daniel A LlanoBeckman Institute for Advanced Science and Technology, Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
Lawrence W DobruckiBeckman Institute for Advanced Science and Technology, Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
Liviu M MiricaDepartment of Chemistry, Beckman Institute for Advanced Science and Technology, The Neuroscience Program, Carle Illinois College of Medicine, University of Illinois at Urbana-Champaign, 600 S. Mathews Avenue, Urbana, Illinois, 61801, USA.ORCID https://orcid.org/0000-0003-0584-9508
University of Illinois Urbana-Champaign · US

Funding

NOVEL BIFUNCTIONAL CHEMICAL AGENTS AS THERANOSTIC TOOLS FOR AMYLOID DISEASESR01GM114588 · NIGMS · WASHINGTON UNIVERSITY · PI MIRICA, LIVIU M. · 2015 to 2019
$1.4M
NIGMS NIH HHS R01 GM114588NIGMS NIH HHS R01GM114588
6 · The paper itself

Abstract

Chromophores with zwitterionic excited-state intramolecular proton transfer (ESIPT) have been shown to have larger Stock shifts and red-shifted emission wavelengths compared to the conventional π-delocalized ESIPT molecules. However, there is still a dearth of design strategies to expand the current library of zwitterionic ESIPT compounds. Herein, a novel zwitterionic excited-state intramolecular proton transfer system is reported, enabled by addition of 1,4,7-triazacyclononane (TACN) fragments on a dicyanomethylene-4H-pyran (DCM) scaffold. The solvent-dependent steady-state photophysical studies, pKa measurements, and computational analysis strongly support that the ESIPT process is more efficient with two TACN groups attached to the DCM scaffold and not affected by polar protic solvents. Impressively, compound DCM-OH-2-DT exhibits a near-infrared (NIR) emission at 740 nm along with an uncommonly large Stokes shift. Moreover, DCM-OH-2-DT shows high affinity towards soluble amyloid β (Aβ) oligomers in vitro and in 5xFAD mouse brain sections, and we have successfully applied DCM-OH-2-DT for the in vivo imaging of Aβ aggregates and demonstrated its potential use as an early diagnostic agent for AD. Overall, this study can provide a general molecular design strategy for developing new zwitterionic ESIPT compounds with NIR emission in vivo imaging applications.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsMiceProtonsSolventsAmyloid beta-PeptidesProtonsSolventsAlzheimer's diseaseamyloid-β oligomersearly diagnosisnear-infrared fluorescence imagingzwitterionic excited-state intramolecular proton transfer

Identifiers

PMID37616059
PMCPMC10840928
OpenAlexW4386117012

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.